$LEXX News

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co.

Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry

Lexaria Announces Effective Date for Reverse Stock Split

LEXX: Dosing Started for Animal & Human GLP-1 Studies

Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate

Lexaria Updates Business Development

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

LEXX: Animal & Human GLP-1 Studies Continue

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June

Lexaria Updates Progress on Human Study #7